Trial Profile
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2015
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Nippon Shinyaku
- 13 Nov 2015 New trial record